Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity
Dan H. Barouch(Beth Israel Deaconess Medical Center), Jaap Goudsmit(Harvard University), Stefan Kostense(Johnson & Johnson (Netherlands)), Michelle A. Lifton(Beth Israel Deaconess Medical Center), Michael H. Newberg(Beth Israel Deaconess Medical Center), Michael Kishko(Beth Israel Deaconess Medical Center), Wouter Koudstaal(Johnson & Johnson (Netherlands)), Birgit Korioth-Schmitz(Beth Israel Deaconess Medical Center), Darci A. Gorgone(University of Vienna), Shawn M. Sumida(Beth Israel Deaconess Medical Center), Gary J. Nabel(National Institutes of Health), Dennis Panicali(Fox Chase Cancer Center), Maria Grazia Pau, Jerome Custers(Janssen (Netherlands)), Diana M. Truitt(Beth Israel Deaconess Medical Center), Janelle C. Arthur(University of North Carolina at Chapel Hill), Norman L. Letvin(Beth Israel Deaconess Medical Center), Menzo Havenga(Unknown)
Cited by 384
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
|Science|2010|1.8k